Why the study?
Does losartan reduce the composite risk of cardiovascular death, stroke, and myocardial infarction compared to atenolol in hypertensive patients with left ventricular hypertrophy across different smoking statuses?
Does losartan reduce the composite risk of cardiovascular death, stroke, and myocardial infarction compared to atenolol in hypertensive patients with left ventricular hypertrophy across different smoking statuses?
The cardiovascular benefits of losartan over atenolol in hypertensive patients with left ventricular hypertrophy are most pronounced in never-smokers and appear to diminish with smoking history.
Answers are grounded in this paper and cite their sources.
May support smoking-stratified losartan use in LVH hypertension; hypothesis-generating, requires RCT confirmation before practice change.
We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy. We compared hazard ratios in 4656 never-smokers, and 3033 previous and 1499 current smokers, adjusting for gender, age, alcohol intake, exercise and race. Composite endpoint rate was higher in previous (28/1000 years), as well as current (39/1000 years) smokers than in never-smokers (21/1000 years). Composite (hazard ratio 0.78, 95% CI 0.65-0.94, p < 0.01) and stroke (hazard ratio 0.61, 95% CI 0.47-0.80], p < 0.001) risks were lower with losartan than atenolol in never-smokers, but not significantly in previous smokers. Drug regimens did not differ in current smokers (composite hazard ratio 0.99, stroke hazard ratio 0.94). Smoking-treatment interactions were non-significant, but a borderline significant trend (p = 0.05) suggested decreasing benefit of losartan vs atenolol for stroke prevention from never- to previous to current smoking status. Smoking increased cardiovascular risk markedly in the LIFE study. The benefit of losartan vs atenolol is consistent with the overall conclusion of the LIFE study, although the treatment effect appeared largest in non-smokers.
No takes yet. Share an insight, caveat, or question.
Reims et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: